Skip to main content
Canna~Fangled Abstracts

An observational study of clinical outcome measures in patients treated with cannabis-based medicinal products on the UK Medical Cannabis Registry

By December 6, 2023December 11th, 2023No Comments

. 2023 Dec 6.

doi: 10.1002/npr2.12403.

Online ahead of print.
Simon Erridge 1 2, Ophilia Leung 1, Carl Holvey 2, Ross Coomber 2 3, Sushil Beri 1 2, Shaheen Khan 2 4, Mark W Weatherall 2 5, James J Rucker 2 6 7, Michael W Platt 2, Mikael H Sodergren 1 2
Affiliations 

Free article

Abstract

Introduction: While there is increasing evidence of the effects of cannabis-based medicinal products (CBMPs) on health-related quality of life (HRQoL), a major limitation of the current literature is the heterogeneity of studied CBMPs. This study aims to analyze changes in HRQoL in patients prescribed a homogenous selection of CBMPs.

Methods: Primary outcomes were changes in patient-reported outcomes (PROMs) at 1, 3, 6, and 12 months from baseline. The secondary outcome was an adverse events analysis. Statistical significance was defined as p < 0.050.

Results: 1378 patients prescribed Adven® CBMPs (Curaleaf International, Guernsey, UK) were included in the final analysis. 581 (42.16%) participants were current users of cannabis at baseline. 641 (46.51%), 235 (17.05%), and 502 (36.43%) patients were treated with oils, dried flowers, or a combination of the two, respectively. Improvements were found in all PROMs in each route of administration at 1, 3, 6, and 12 months from baseline (p < 0.010). Those prescribed dried flower only or both oils and dried flower experienced greater improvements in GAD-7, SQS, and EQ-5D-5L index values at 12 months (p < 0.050). There was no difference in outcomes between those prescribed dried flower only or dried flower with oils (p > 0.050). 3663 (265.82%) adverse events were reported by 297 (21.55%) patients.

Conclusion: There was an associated improvement in self-reported anxiety, sleep quality, and HRQoL in patients treated with the CBMPs. Those prescribed treatment formulations including dried flower were most likely to show a clinical improvement. However, these results must be interpreted with caution given the limitations of study design.

Keywords: anxiety, cannabidiol, cannabis, sleep, tetrahydrocannabinol

PubMed Disclaimer

References

REFERENCES

    1. Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ. 2019;1141:365. https://doi.org/10.1136/bmj.l1141
    1. Case P. The NICE guideline on medicinal cannabis: keeping Pandora’s box shut tight? Med Law Rev. 2020;28(2):401-411.
    1. Banerjee R, Erridge S, Salazar O, Mangal N, Couch D, Pacchetti B, et al. Real world evidence in medical cannabis research. There Innov Regul Sci. 2021;56(2):8-24. https://doi.org/10.1007/s43441-021-00346-0
    1. National Center for Biotechnology Information. PubChem Compound Summary for CID 644019, Cannabidiol. https://pubchem.ncbi.nlm.nih.gov/compound/Cannabidiol [Accessed Feb 25, 2023].
    1. Berman P, Futon K, Lewitus GM, Much D, Benami M, Shlomi T, et al. A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in cannabis. Sci Rep. 2018;8:14280. https://doi.org/10.1038/s41598-018-32651-4

LinkOut – more resources

  • Full Text Sources

Leave a Reply